Navigation Links
Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
Date:2/14/2011

DURHAM, N.C., Feb. 14, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.

Proceeds from this financing will be used to support the development of Chimerix's two clinical-stage candidates, CMX001 and CMX157.  CMX001 is in clinical development as a broad spectrum antiviral for the treatment of life-threatening viral infections in immunocompromised patients, and has a potential dual use as a medical countermeasure in the event of a smallpox release.  Chimerix is evaluating CMX001 in an ongoing Phase 2 clinical study of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients, and in an Open-Label Study under an expanded access protocol for the treatment of critically-ill patients with any of 12 different double-stranded DNA viral infections.  A Phase 2 clinical trial of CMX001 in pediatric and adult hematopoietic stem cell transplant patients with adenovirus related diseases is currently being initiated. Chimerix recently completed a Phase 1 clinical trial of CMX157, a potent nucleoside analogue in development for the treatment of HIV infections, including those caused by multi-drug resistant viruses.

"Development of our two clinical-stage antiviral therapeutics is rapidly accelerating.  We are truly pleased to receive this strong support from leading life science investors for Chimerix's ground-breaking programs," said Kenneth I. Moch, President and CEO of Chimerix. "We are extremely enthusiastic about the very real prospects for Chimerix's drugs to dramatically improve the treatment of deadly viral infections."  

<
'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
2. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
3. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
4. Chimerix to Present at Upcoming Investor Conferences
5. Chimerix Initiates Phase 1 Study of CMX157
6. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
7. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
8. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
9. Chimerix Joins International Network of Organizations to Cure Malaria
10. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
11. Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimers Disease Drug Treatment Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... July 6, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ... agreement with Novella Clinical (Novella), to conduct ... with newly diagnosed glioblastoma. Novella is a full-service, global ... small to mid-sized oncology companies. The ICT-107 phase 3 ... US, Europe and ...
(Date:7/3/2015)... , July 3, 2015 /PRNewswire/ ... hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Innovation in Science" -jatkokoulutusohjelmaan 22.7.2015 ... Gesellschaftin (LBG) tekemän, kansainvälisiä tutkijoita ... terveystieteiden kaksi suurinta haastetta ovat ...
(Date:7/3/2015)... Forskare kan ansöka ... http://www.openinnovationinscience.at till det återkommande utbildningsprogrammet "Lab ... i Wien .  ... forskare och vetenskapsmän som genomfördes av Ludwig ... utmaningar bristen på incitament för att undersöka ...
(Date:7/3/2015)... Forskere kan ansøge ... http://www.openinnovationinscience.at om efteruddannelsesprogrammet "Lab for Open ... Wien .  ... og videnskabsmænd foretaget af Ludwig Boltzmann Gesellschaft ... sundhedsvidenskaben manglen på incitamenter til at undersøge ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3
... Inc. (Amex: CUR ) is filing suit today ... withheld crucial,information highly material to the patentability of StemCells, ... done with the intent to deceive,the United States Patent ... As,a result of these actions, Neuralstem is asking for ...
... Entrust, Inc. (Nasdaq: ENTU ),Chairman, President and ... of Technology Luncheon on Thursday, May 8, at 12 ... Conner will address the history of attacks on digital ... the growing threats.,Conner also will discuss how the cybersecurity ...
... - New Member Complements Board With Significant Financial and Operational ... ... May 7 Nventa Biopharmaceuticals,Corporation (TSX: NVN) announced today the appointment ... serves as the chief,operating officer and chief financial officer of Aryx ...
Cached Biology Technology:Neuralstem Sues StemCells, Inc. Over New Patent 2Neuralstem Sues StemCells, Inc. Over New Patent 3Entrust Chairman, President and CEO Bill Conner to Present at 8th Annual State of Technology Luncheon 2Nventa Appoints John Varian to Board of Directors 2
(Date:6/17/2015)... , June 17, 2015 QIAGEN ... launched new Investigator ® STR assay kits for analysis ... United States . The new genetic fingerprint kits provide ... (short tandem repeats or STRs) for DNA matching. They incorporate ... of DNA in each sample, a novel QIAGEN technology that ...
(Date:6/16/2015)... 2015 Fingerprint Cards has received an ... the company,s portfolio from one of its module partners in ... take place during the third quarter 2015. The sensors will ... . Jörgen Lantto, CEO of FPC, comments: " ... growing interest from smartphone OEMs in integrating touch fingerprint sensors ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... its patent to electronically capture, analyze and identify ... facial recognition methods. This system can: ... by an enrollment and subsequent sign-on process is ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... new clues that may explain why Graves?disease (GD) attacks ... to bulge painfully from their sockets, as in the ... Stein Eye Institute and Harbor-UCLA Medical Center discovered defects ... Reported March 1 in the Journal of Immunology, their ...
... created an ocean model so realistic that the virtual forests ... patterns that precisely mimic their real-world counterparts. , This model ... diversity of the invisible forests living in our oceans-tiny, single-celled ... oxygen we breathe on Earth. And it does so in ...
... Epstein-Barr viruses inside tumors as a way to ... destroy their tumors. They say this strategy could offer ... Epstein-Barr, including at least four different types of lymphoma ... 1 issue of Clinical Cancer Research, a team of ...
Cached Biology News:UCLA study uncovers clues for why Graves' disease attacks the eyes 2MIT's ocean model captures diversity of underwater forests 2MIT's ocean model captures diversity of underwater forests 3Researchers wake up viruses inside tumors to image and then destroy cancers 2Researchers wake up viruses inside tumors to image and then destroy cancers 3
...
...
... XL provides RS232/Serial data collection and automation ... Complete instrument integration with Microsoft Excel ... balances, pH meters, titrators, density meters, force ... and serial instruments can be added and ...
... the family of calcium binding proteins such as ... of an alpha and beta chain whereas S100B ... protein is also expressed in the antigen presenting ... and interdigitating reticulum cells in the paracortex of ...
Biology Products: